公开(公告)号：US20200175607A1

公开(公告)日：2020-06-04

申请号：US16208155

申请日：2018-12-03

Applicant: Charles Ding ,  Kebin Lu ,  Thomas Shieh

Inventor： Charles Ding ,  Kebin Lu ,  Thomas Shieh

IPC: G06Q40/00 ,  G06F17/10 ,  G06N7/00

Abstract: Segmentation algorithms may operate on vast quantities of data to segment the data into a useful data the model. The segmentation data model may then be applied to additional data that may be received in real time. Further, the real time data may be given a score based on the segmentation model and the desires of the user. The segmentation of the data and the score may be returned to a user and the user may determine if additional actions make logical sense based on the score and segmentation.

公开(公告)号：US08703742B2

公开(公告)日：2014-04-22

申请号：US13227444

申请日：2011-09-07

Applicant: Vincent S. Hernandez ,  Charles Ding ,  Jacob J. Plattner ,  Michael Richard Kevin Alley ,  Fernando Rock ,  Suoming Zhang ,  Eric Easom ,  Xianfeng Li ,  Ding Zhou

Inventor： Vincent S. Hernandez ,  Charles Ding ,  Jacob J. Plattner ,  Michael Richard Kevin Alley ,  Fernando Rock ,  Suoming Zhang ,  Eric Easom ,  Xianfeng Li ,  Ding Zhou

IPC: A61K31/69 ,  A61P31/04 ,  A61P31/00 ,  A61P31/06 ,  C07F5/02 ,  C12N9/99

CPC classification number: C07F5/025

Abstract: This invention relates to, among other items, benzoxaborole compounds and their use for treating bacterial infections.

Abstract translation: 本发明涉及苯并恶唑化合物及其用于治疗细菌感染的用途。

公开(公告)号：US20070287713A1

公开(公告)日：2007-12-13

申请号：US11779319

申请日：2007-07-18

Applicant: Peter Cheng ,  Sean Chen ,  Pratik Devasthale ,  Charles Ding ,  Timothy Herpin ,  Shung Wu ,  Hao Zhang ,  Wei Wang ,  Xiang-Yang Ye

Inventor： Peter Cheng ,  Sean Chen ,  Pratik Devasthale ,  Charles Ding ,  Timothy Herpin ,  Shung Wu ,  Hao Zhang ,  Wei Wang ,  Xiang-Yang Ye

IPC: A61K31/41 ,  A61K31/42 ,  A61K31/44 ,  A61K31/445 ,  A61K31/4965 ,  A61K31/497 ,  A61K31/505 ,  A61P3/10 ,  C07D239/02 ,  C07D257/00 ,  C07D263/30 ,  C07D271/06 ,  C07D401/02 ,  C07D403/02 ,  C07D413/02

CPC classification number: C07D413/12 ,  C07D413/14

Abstract: wherein Z1 is (CH2)q or C═O; Z2 is (CH2)p or C═O; D is —CH═ or C═O or (CH2)m where m is 0, 1, 2 or 3; n=0, 1 or 2; p=1 or 2; q=0, 1 or 2; Q is C or N; A is (CH2)x where x is 1 to 5, or A is (CH2)x1, where x1 is 1 to 5 with an alkenyl bond or an alkynyl bond embedded anywhere in the chain, or A is —(CH2)x2—O—(CH2)x3— where x2 is 0 to 5 and x3 is 0 to 5, provided that at least one of x2 and x3 is other than 0; B is a bond or is (CH2)x4 where x4 is 1 to 5; X is CH or N; X2 is C, N, O or S; X3 is C, N, O or S; X4 is C, N, O or S; X5 is C, N, O or S; X6 is C, N, O or S; provided that at least one of X2, X3, X4 X5 and X6 is N; and at least one of X2, X3, X4 X5 and X6 is C. R1 is H or alkyl; R2 is H, alkyl, alkoxy, halogen, amino, substituted amino or cyano; R2a, R2b and R2c may be the same or different and are selected from H, alkyl, alkoxy, halogen, amino, substituted amino or cyano; and R3, E, Z and Y are as defined herein.

公开(公告)号：US20120115813A1

公开(公告)日：2012-05-10

申请号：US13227444

申请日：2011-09-07

Applicant: Vincent S. Hernandez ,  Charles Ding ,  Jacob J. Plattner ,  Michael Richard Kevin Alley ,  Fernando Rock ,  Suoming Zhang ,  Eric Easom ,  Xianfeng Li ,  Ding Zhou

Inventor： Vincent S. Hernandez ,  Charles Ding ,  Jacob J. Plattner ,  Michael Richard Kevin Alley ,  Fernando Rock ,  Suoming Zhang ,  Eric Easom ,  Xianfeng Li ,  Ding Zhou

IPC: A61K31/69 ,  A61P31/04 ,  A61P31/00 ,  A61P31/06 ,  C07F5/04 ,  C12N9/99

CPC classification number: C07F5/025

Abstract: This invention relates to, among other items, benzoxaborole compounds and their use for treating bacterial infections.

Abstract translation: 本发明涉及苯并恶唑化合物及其用于治疗细菌感染的用途。

公开(公告)号：US20060019986A1

公开(公告)日：2006-01-26

申请号：US11186425

申请日：2005-07-21

Applicant: Charles Ding ,  Zhenkun Ma ,  Jing Li ,  Susan Harran ,  Yong He ,  Keith Minor ,  In Kim ,  Jamie Longgood ,  Yafei Jin ,  Keith Combrink

Inventor： Charles Ding ,  Zhenkun Ma ,  Jing Li ,  Susan Harran ,  Yong He ,  Keith Minor ,  In Kim ,  Jamie Longgood ,  Yafei Jin ,  Keith Combrink

IPC: A61K31/4745 ,  C07D491/14

CPC classification number: C07D401/12 ,  C07D455/02

Abstract: Rifamycin derivatives having the following structure of general formula I (both hydroquinone and corresponding quinone (C1-C4) forms): or its salts, hydrates or prodrugs thereof; wherein a preferred R1 comprises hydrogen or acetyl and a prefered R2 comprises hydrogen, methyl or other lower alkyls; wherein asterik (*) denotes the carbon bearing the chiral center, wherein absolute configuration is assigned as R or S. Methods of preparation of the aforementioned rifamycin derivatives are also described. The compounds exhibit antimicrobial activities, including activities against drug-resistant microorganisms.

Abstract translation: 具有以下通式I结构的利福霉素衍生物（氢醌和对应的醌（C 1 -C 4））形成）：或其盐，水合物或前药; 其中优选的R 1包括氢或乙酰基，优选的R 2 H 2包括氢，甲基或其它低级烷基; 其中asterik（*）表示带有手性中心的碳，其中绝对构型被指定为R或S.还描述了上述利福霉素衍生物的制备方法。 这些化合物表现出抗菌活性，包括抵抗耐药微生物的活性。

公开(公告)号：US20060019985A1

公开(公告)日：2006-01-26

申请号：US11186187

申请日：2005-07-21

Applicant: Zhenkun Ma ,  Jing Li ,  Susan Harran ,  Yong He ,  Keith Minor ,  In Kim ,  Charles Ding ,  Jamie Longgood ,  Yafei Jin ,  Keith Combrink

Inventor： Zhenkun Ma ,  Jing Li ,  Susan Harran ,  Yong He ,  Keith Minor ,  In Kim ,  Charles Ding ,  Jamie Longgood ,  Yafei Jin ,  Keith Combrink

IPC: A61K31/4745 ,  C07D491/14

CPC classification number: C07D401/12 ,  C07D455/02

Abstract: Novel rifamycin derivatives of formula I (both hydroquinone and corresponding quinone (C1-C4) forms): or their salts, hydrates or prodrugs thereof, wherein: a preferred R comprises hydrogen, acetyl; L is a linker, a preferred linker group elements selected from any combination of 1 to 5 groups shown FIG. 1, provided L is not wherein R1 is H, methyl or alkyl. The inventive compounds exhibit valuable antibiotic properties. Formulations having these compounds can be used in the control or prevention of infectious diseases in mammals, both humans and non-humans. In particular, the compounds exhibit a pronounced antibacterial activity, even against multiresistant strains of microbes.

Abstract translation: 式I的新型利福霉素衍生物（氢醌和相应的醌（C 1 -C 4））形成）：或其盐，水合物或前药，其中：优选的R 包括氢，乙酰基; L是接头，优选的连接基团元素选自1至5个组的任何组合，如图1所示。 1，其中L不是其中R 1是H，甲基或烷基。 本发明化合物显示出有价值的抗生素性质。 具有这些化合物的制剂可以用于控制或预防哺乳动物，包括人和非人的感染性疾病。 特别地，这些化合物甚至显示出显着的抗菌活性，即使是针对多抗菌菌株的微生物。

公开(公告)号：US20050209210A1

公开(公告)日：2005-09-22

申请号：US11034279

申请日：2005-01-12

Applicant: Charles Ding ,  Yafei Jin ,  Jamie Longgood ,  Zhenkun Ma ,  Jing Li ,  In Kim ,  Keith Minor ,  Susan Harran

Inventor： Charles Ding ,  Yafei Jin ,  Jamie Longgood ,  Zhenkun Ma ,  Jing Li ,  In Kim ,  Keith Minor ,  Susan Harran

IPC: A61K31/4709 ,  C07D491/14 ,  C07D498/08 ,  C07D519/00

CPC classification number: C07D498/08 ,  C07D519/00

Abstract: The present invention relates to rifamycin 3-iminomethylenyl (—CH═N—) derivatives having antimicrobial activities, including activities against drug-resistant microorganisms. The claimed rifamycin derivative has a rifamycin moiety covalently linked to a linker through an iminomethylenyl (—CH═N—) group at the C-3 carbon of the rifamycin moiety and the linker is, in turn, covalently linked to a quinolone structure or its pharmacophore within the DNA gyrase and topoisomerase IV inhibitor family. The inventive rifamycins are novel and exhibit activity against both rifampin and ciprofloxacin-resistant microorganisms.

Abstract translation: 本发明涉及具有抗菌活性的利福霉素3-亚氨基亚甲基（-CH-N-）衍生物，其包括抗药性微生物的活性。 所要求的利福霉素衍生物具有通过利莫霉素部分的C-3碳上的亚氨基亚甲基（-CH-N-）基团与连接体共价连接的利福霉素部分，并且连接体又与喹诺酮结构共价连接或其 DNA促旋酶和拓扑异构酶IV抑制剂家族内的药效团。 本发明的利福霉素是新颖的，并且表现出抵抗利福平和环丙沙星抗性微生物的活性。

公开(公告)号：US20050119312A1

公开(公告)日：2005-06-02

申请号：US11016183

申请日：2004-12-17

Applicant: Peter Cheng ,  Sean Chen ,  Charles Ding ,  Timothy Herpin

Inventor： Peter Cheng ,  Sean Chen ,  Charles Ding ,  Timothy Herpin

IPC: A61K31/41 ,  A61K31/42 ,  A61K31/435 ,  A61K31/50 ,  A61K31/52 ,  C07D233/54 ,  C07D249/06 ,  C07D263/32 ,  C07D271/06 ,  C07D413/12 ,  C07D417/14 ,  A61K31/4439 ,  A61K31/444 ,  C07D413/14

CPC classification number: C07D233/64 ,  C07D249/06 ,  C07D263/32 ,  C07D271/06 ,  C07D413/12

Abstract: Compounds are provided which are useful as antidiabetic agents and antiobesity agents and have the structure wherein m is 0, 1 or 2; n is 0, 1 or 2; Q is C or N; A is (CH2)x where x is 1 to 5, or A is (CH2)x1 where x1 is 1 to 5 with an alkenyl bond or an alkynyl bond embedded anywhere in the chain, or A is —(CH2)x2—O—(CH2)x3— where x2 is 0 to 5 and x3 is 0 to 5, provided that at least one of x2 and x3 is other than 0; B is a bond or is (CH2)x4 where x4 is 1 to 5; X is CH or N; X2 is C, N, O or S; X3 is C, N, O or S; X4 is C, N; O or S; X5 is C, N, O or S; X6 is C, N, O or S; provided that at least one of X2, X3, X4 X5 and X6 is N; and at least one of X2, X3, X4 X5 and X6 is C, and specifically excluding the structure(s) as shown below: where X2═N, X3═C, X4═O or S, Z=O or a bond R1 is H or alkyl; R2 is H, alkyl, alkoxy, halogen, amino or substituted amino or cyano; R2a, R2b and R2c may be the same or different and are selected from H, alkyl, alkoxy, halogen, amino or substituted amino or cyano; and R3 and Y are as defined herein, which compounds are useful in treating diabetes and obesity.

公开(公告)号：US20190026743A1

公开(公告)日：2019-01-24

申请号：US16138288

申请日：2018-09-21

Applicant: Charles DING ,  Aoyu CHEN ,  Suyun XU ,  Kevin SIEGEL

Inventor： Charles DING ,  Aoyu CHEN ,  Suyun XU ,  Kevin SIEGEL

IPC: G06Q20/40

Abstract: Embodiments of the invention relate in part to determining a testing model and providing a testing transaction score for transactions. The testing transaction score may indicate a likelihood that the transaction is a testing transaction. One embodiment of the invention discloses a method comprising receiving a first authorization message for a first transaction using an account, determining a testing transaction score for the first transaction using a testing model, and determining that the first transaction is a testing transaction based on the testing transaction score, wherein the testing transaction score for the first transaction is used for declining a second transaction using the same account conducted after the first transaction.

公开(公告)号：US20140324699A1

公开(公告)日：2014-10-30

申请号：US14263654

申请日：2014-04-28

Applicant: Charles Ding ,  Aoyu Chen ,  Suyun Xu ,  Kevin Siegel

Inventor： Charles Ding ,  Aoyu Chen ,  Suyun Xu ,  Kevin Siegel

IPC: G06Q20/40

CPC classification number: G06Q20/4016

Abstract: Embodiments of the invention relate in part to determining a testing model and providing a testing transaction score for transactions. The testing transaction score may indicate a likelihood that the transaction is a testing transaction. One embodiment of the invention discloses a method comprising receiving a first authorization message for a first transaction using an account, determining a testing transaction score for the first transaction using a testing model, and determining that the first transaction is a testing transaction based on the testing transaction score, wherein the testing transaction score for the first transaction is used for declining a second transaction using the same account conducted after the first transaction.

Abstract translation: 本发明的实施例部分地涉及确定测试模型并提供交易的测试交易分数。 测试交易分数可能表明交易是测试交易的可能性。 本发明的一个实施例公开了一种方法，包括使用帐户接收第一交易的第一授权消息，使用测试模型确定第一交易的测试交易得分，以及基于所述测试确定所述第一交易是测试交易 交易分数，其中第一交易的测试交易分数用于使用在第一交易之后进行的相同账户拒绝第二交易。